CÁNCER DE MAMA
Hospital Clinico Universitario de Valencia
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clinico Universitario de Valencia (29)
2024
-
Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study
Breast, Vol. 77
-
Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer
JAMA network open, Vol. 7, Núm. 4, pp. e247811
-
Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial
eClinicalMedicine, Vol. 71
2023
-
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry
Breast Cancer Research and Treatment, Vol. 201, Núm. 2, pp. 151-159
-
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme
European Journal of Cancer, Vol. 182, pp. 3-14
2022
-
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
Frontiers in Oncology, Vol. 11
-
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
Breast, Vol. 66, pp. 77-84
2021
2019
-
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
Frontiers in Oncology, Vol. 9, Núm. APR
-
Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
Therapeutic Advances in Medical Oncology, Vol. 11
-
Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)
Scientific Reports, Vol. 9, Núm. 1
2018
-
Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/ HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial a randomized phase 3 clinical trial
JAMA Oncology, Vol. 4, Núm. 3, pp. 302-308
-
Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study
European Journal of Cancer, Vol. 94, pp. 199-205
-
Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy
Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1548-1556
2017
-
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624
2016
-
Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428
2014
-
Treatment innovations for metastatic breast cancer: Nanoparticle albumin-bound (NAB) technology targeted to tumors
Critical Reviews in Oncology/Hematology, Vol. 89, Núm. 1, pp. 62-72
2013
-
Finding the right dose of fulvestrant in breast cancer
Cancer Treatment Reviews, Vol. 39, Núm. 2, pp. 136-141
-
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study
Journal of Clinical Oncology
2010
-
Current controversies in the management of breast cancer
Clinical and Translational Oncology, Vol. 12, Núm. 4, pp. 278-286